Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Clathrate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Clathrate. Displaying page 1 of 1.
    EudraCT Number: 2006-004899-13 Sponsor Protocol Number: 310882 Start Date*: 2008-01-16
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: A multi-center, open-label, randomized, controlled, parallel-group study to assess efficacy and safety of an extended flexible regimen of the combined oral contraceptive SH T00186D (0.02 mg ethinyl...
    Medical condition: women suffering from primary dysmenorrhea
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002125-32 Sponsor Protocol Number: 308683 Start Date*: 2005-12-22
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: A multicenter, open, randomized, parallel-group comparison to assess the safety and efficacy of the oral contraceptive SH T 00186 D (0.02 mg ethinylestradiol as betadex clathrate and 3 mg drospiren...
    Medical condition: healthy volunteers requesting oral contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001789-13 Sponsor Protocol Number: QUINA/2012 Start Date*: 2012-11-16
    Sponsor Name:Instituto de Investigacion Sanitaria La e
    Full Title: Double-blind, randomized, controlled contraceptives, parallel group, to assess the effect on nerve fibers in patients diagnosed with endometriosis grade III / IV symptomatic ascending-dose oral qui...
    Medical condition: Endometriosis grade III/IV
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004522-16 Sponsor Protocol Number: DU176b-C-U301 Start Date*: 2009-05-20
    Sponsor Name:Daiichi Sankyo Pharma Development
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR EVALUATION OF EFFICACY AND SAFETY OF DU-176B VERSUS WARFARIN IN SUBJECTS WITH ATRIAL FIBRIL...
    Medical condition: Reduction of Stroke and/or systemic embolic event (SEE) in subjects with atrial fibrillation (AF).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) SE (Completed) EE (Completed) FI (Completed) NL (Completed) PT (Completed) DK (Completed) ES (Completed) CZ (Completed) IT (Completed) BG (Completed) HU (Completed) SK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019902-17 Sponsor Protocol Number: BAY86-5300/14701 Start Date*: 2010-12-09
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multicenter, open-label, randomized, controlled, two-arm study to assess compliance with daily tablet intake of women on treatment with the oral contraceptive SH T00186D/BAY 86-5300 (0.02 mg ethi...
    Medical condition: Contraception
    Disease: Version SOC Term Classification Code Term Level
    12.1 10030970 Oral contraception LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003148-21 Sponsor Protocol Number: DU176b-F-E308 Start Date*: 2014-06-17
    Sponsor Name:Daiichi Sankyo Development Ltd
    Full Title: A prospective, randomised, open-label, blinded endpoint evaluation (PROBE) parallel group study comparing edoxaban (DU-176b) with enoxaparin/warfarin followed by warfarin alone in subjects undergoi...
    Medical condition: Stroke and thromboembolism prevention in patients with non-valvular atrial fibrillation (NVAF) undergoing planned electrical cardioversion.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) DE (Completed) GB (Completed) HU (Completed) IT (Completed) DK (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) RO (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-014290-40 Sponsor Protocol Number: DU176b-D-U305 Start Date*: 2010-02-10
    Sponsor Name:Daiichi Sankyo Development Limited
    Full Title: A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfar...
    Medical condition: Reduction of the risk of symptomatic recurrent venous thromboembolic complications in patients with acute symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    14.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) SE (Completed) FR (Completed) EE (Completed) BE (Completed) AT (Completed) ES (Completed) DK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002181-38 Sponsor Protocol Number: WARCEF Start Date*: 2004-10-22
    Sponsor Name:NIH-National Institut of Health - NINDS-National Institut of Neurogical Disorders and Stroke
    Full Title: Warfarin versus Aspirin in Reduced Ejection Fraction.
    Medical condition: Patients with left ventricular disfunction with ejection fraction less or equal to 35%.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 23:36:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA